Background Screening of multiple endocrine neoplasia type 1 (MEN-1) patients is widely
recommended because one-fifth succumb to malignant neoplasms. However …

PURPOSE: To perform clinical and genetic screening for multiple endocrine neoplasia type
1 (MEN1) in patients at the Academic Hospital of the University of São Paulo School of …

Background: Some experts maintain that (1)> 90% of patients with multiple endocrine
neoplasia type 1 (MEN1) are first seen with hyperparathyroidism (HPTH) so that routine …

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder
characterized by the combined occurrence of parathyroid, pancreatic islet and anterior …

Multiple endocrine neoplasia type 1 (MEN 1) is characterized by the combined occurrence,
to variable degree, of hyperparathyroidism (HPT)(85.7% of cases according to the French …

Screening for multiple endocrine neoplasia type 1 (MEN1) may be conducted for a variety of
reasons. The principal aims may be more or less scientific, such as early identification of the …

The clinical and biochemical features of multiple endocrine neoplasia type 1 are presented
with a focus on methods for the early detection of the parathyroid, pituitary, and endocrine …

Objective To determine the benefit of periodical clinical screening of carriers of a mutation in
the multiple endocrine neoplasia type 1 (MEN-1) gene, because any useful discussion …

Early identification of pancreaticoduodenal endocrine tumors (PETs) in multiple endocrine
neoplasia type 1 (MEN-1) is mandatory, because these tumors represent the most common …

Prospective randomized data are lacking, but current clinical expert guidelines recommend
annual screening examinations, including laboratory assessments and various imaging …